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 Weaning is a stressful event for pigs and causes decreased feed intake, poor growth, and 
increased susceptibility to disease. Previous studies have shown that syndyphalin-33, a synthetic 
opioid, was effective in increasing feed intake, abrogating the changes in appetite regulating 
genes during weaning, and abrogating the effects of a salmonella challenge on immune cells in 
newly-weaned pigs. However, there are several concerns associated with the administration of an 
opioid in commercial swine operations. Low-dose naltrexone (an opioid antagonist) has been 
used to alleviate symptoms from fibromyalgia and Crohn’s disease in humans. As inflammation 
is a common factor in both auto-immune diseases in humans and weaning stress in pigs, a logical 
next-step would be to examine the effects of low-dose naltrexone on pigs at weaning. In this 
study, low-dose naltrexone administration was evaluated for its affects on feed intake, growth, 
endocrine, and immune parameters in newly weaned pigs. Four treatments of 0 mg/day (d), 1 
mg/d, 5 mg/d, 10 mg/d naltrexone were administered orally daily beginning 2 wk prior to 
weaning to 48 commercial crossbred pigs. Each treatment group included 12 pigs. Body weights 
and blood samples were collected d 0 and at 1, 4, and 7 post-weaning. All animals treated with 
naltrexone had increased total gain as compared to the control animals (P < 0.05). A decrease in 
feed intake was seen in animals treated with 5 mg/d naltrexone as compared to the control 
animals (P < 0.05). Plasma cortisol concentrations were similar to previously published 
concentrations and increased 1 d post-weaning in the control animals (P < 0.01). Animals treated 
with 10 mg/d naltrexone had higher plasma concentrations of cortisol relative to all other 
treatments (P < 0.01). On 1 d post-weaning, animals treated with 1 mg/d and 5 mg/d naltrexone 
had lower plasma cortisol concentration than the controls (P < 0.01), and by d 4 post-weaning, 




animals (P < 0.01). As a non-opioid, oral low-dose naltrexone may be a promising therapy to 
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Introduction: The Issue with Weaning 
The weaning of swine occurs between twenty one and twenty eight days of age (Ko et al., 
2015). At weaning, pigs are exposed to new stressors such as social hierarchy, environments, 
handlers, pathogens, nutritional factors, and feeding systems. These stressors not only decrease 
feed intake and cause poor growth, but also increase disease susceptibility (Matteri et al, 2000; 
Kojima et al., 2007, 2008; Jenkins et al., 2009). The post-wean growth lag causes problems for 
the swine industry because it reduces post-weaning average daily gain, reduces feed efficacy, 
and increases the time needed for animals to reach the desired market weight. 
This literature review will cover background information regarding the physiological 
effects of weaning on the pig, current techniques used to reduce the post-weaning growth lag, 
and the use of low-dose naltrexone as a potential aid in negating the undesirable effects of 
weaning-related stress.  
 
Behavior and Growth 
 At weaning, pigs are removed from their dams and mixed together in group pens, usually 
in a separate building from other, older animals. Pigs have a social hierarchy that includes a 
dominant animal and subordinate animals. Fighting erupts quickly after being placed together, 
forcing each pig to battle for dominance. Establishment of the new hierarchy is usually complete 
within 24 hours of mixing (Symoens and Van Den Brande, 1969). During fights, they are not 
ingesting calories for growth. In fact, they are using energy to fight and heal rather than to grow 






Cortisol: Physiological Stress Indicator 
Release of cortisol is reviewed in detail by Matousek et al. (2010). A stress stimulus 
initiates an action potential, transported by sensory nerves to the hypothalamic-pituitary-adrenal 
(HPA) axis. Activation of the hypothalamus initiates the secretion of corticotrophin-releasing 
hormone (CRH) from neurosecretory cells into the primary capillary plexus of the hypophyseal 
portal system. Corticotrophin-releasing hormone exits the portal system at the secondary 
capillary plexus and stimulates corticotrophs in the anterior pituitary to produce 
adrenocorticotrophic hormone (ACTH).  The corticotrophs release ACTH into the secondary 
capillary plexus to circulate through the body to the adrenal glands. Activation of cells in the 
zona fasciculata of the adrenal cortex results in the release of cortisol into systemic circulation. 
Cortisol is a glucocorticoid-steroid hormone that is involved in many pathways, including 
immunological functions and appetite regulation (Webster et al., 2002; Liu et al., 2007). Because 
of its quick release during a stress-stimulus, cortisol measurements are commonly used as an 
indicator of stress. Weaning results in a transient but marked increase in cortisol concentrations 
that usually returns to pre-wean levels by four days post weaning (Le Dividich and Seve, 2000; 
Kojima et al., 2008; Cooper et al., 2009). Cortisol’s specific action in the appetite pathway and 
immunological functions will be discussed in subsequent sections. 
 
Corticosterioid-Binding Globulin 
Corticosteriod-binding globulin (CBG) is a transport carrier glycoprotein found in 
circulation after its production and release from the liver. The majority of cortisol found in blood 
is bound to CBG (Adcock et al., 2006). Only free cortisol has been shown to be biologically 




Henning, 1989; Rosner, 1990; Adcock et al., 2006). When blood cortisol concentrations increase 
due to stressful situations, CBG concentrations decrease, allowing cortisol to be bio-available 
(Kojima et al., 2008; Cooper et al., 2009; Henley and Lightman, 2011).  
 
Free Cortisol Index 
 The free cortisol index (FCI) is an indicator of unbound cortisol in circulation. The FCI is 
determined for each sample by dividing the concentration of cortisol by the concentration of 
CBG (Adcock et al., 2007). Previously, FCI has been used as an estimate of free cortisol in 
humans (le Roux et al., 2002, 2003), and the use of FCI in swine was validated by Adcock and 
colleagues in 2006. During weaning in pigs, the FCI increases as a result of an increase in serum 
concentrations of cortisol combined with a decrease in plasma concentrations in CBG (Heo et al., 
2003; Kojima et al., 2008; Cooper et al., 2009). It should be noted that the FCI, as a ratio, is not a 
sensitive indicator of free cortisol; therefore small changes in cortisol concentrations will 
minimally affect the resulting FCI. 
 
Effects of Weaning on Appetite 
Appetite is controlled by orexogenic and satiety centers in the hypothalamus (Wynne et 
al., 2005). The following is a summary of appetite control from reviews by Wynne et al. (2005) 
and Stanley et al. (2005). Leptin and insulin function as appetite suppressants through the same 
pathway. Leptin is produced and released by adipocytes, while insulin is produced by pancreatic 
beta-cells and released from the liver. Both hormones stimulate pro-opiomelanocortin (POMC) 
to increase release of alpha-melanocyte stimulating hormone (MSH). Alpha-MSH subsequently 




stimulators compete with appetite inhibitors to bind the Melanocortin-4 receptor (MC4R) 
(Wynne et al., 2005; Stanley et al., 2005).  Melanocortin-4 receptor is found in the central 
nervous system and is part of the melanocortin pathway; a major controller of appetite. Agouti-
related protein (AgRP) competes with alpha-MSH to bind with MC4R. However, in stressed 
animals with increased plasma cortisol concentrations, the production of AgRP is decreased and 
alpha-MSH is allowed to bind to MC4R at a higher rate, therefore, decreasing appetite 
stimulation (Wynne et al., 2005; Stanley et al., 2005). The post-weaning growth lag in pigs is 
well recognized and clearly associated with reduced feed intake (Bark et al., 1986; McCracken et 
al., 1995; Cooper et al., 2009). The increased binding of MC4R by alpha-MSH was seen in 
experiments involving rats performed by Kas and colleagues (2005) and Liu and others (2007).  
 
Effects of Weaning on Immunological Functions 
The immune system is important for removal of foreign cells/material and initiation of 
healing (Donaldson, 2007). The immune system is composed many types of leukocytes: 
basophils, neutrophils, eosinophils, monocytes, and lymphocytes. Basophils are mediators of 
inflammation that produce histamine and bradykinin, while neutrophils are small phagocytic 
short-lived cells. Eosinophils attack multi-cellular parasites in addition to detoxifying histamines 
from basophils.  Monocytes circulate in the blood and are long-lived phagocytic cells 
(Donaldson, 2007). Lymphocytes can be roughly classified as one of two different types of cells: 
B- cells or T-cells. T-cells have three specific actions: recognition of the pathogen, initial release 
of cytokines, and destruction of virus infected cells. B-cells produce and release antibodies. 




2007; Moore, 2007). The response to infection by release of antibodies is referred to as the 
humoral response of the immune system.  
Leukocytes contain receptors for pathogens in their cell membranes, making them 
capable of initiating the immune response. When the immune system is activated, many different 
immune cells can release histamine and chemotaxins, which cause blood vessels in the affected 
area to dilate and become more porous, allowing increased blood flow and migration of 
leukocytes into the area (Donaldson, 2007). Chemotaxins promote the release of leukocytes from 
storage in bone marrow for additional support against the pathogens (Moore, 2007). In addition 
to the humoral response, a cellular response is also initiated when foreign cells/material enters 
the body. The cellular response includes the production and release of cytokines. Cytokines can 
be either pro- or anti-inflammatory in nature and are regulated by a positive feed-back system to 
further increase the number of circulating cytokines and cytokine receptors. Pro-inflammatory 
cytokines such as interleukin-1 and interleukin-6 increase the number of migrating leukocytes to 
the site of infection (Donaldson, 2007). This causes a local increase in temperature and swelling. 
Interleukin- 1 also binds to the thermoregulatory center of the hypothalamus initiating a febrile 
response (Eskilsson et al., 2014). Other cytokines, such as interleukin-10 and interleukin-4 are 
anti-inflammatory. They are released by T cells to stimulate and promote proliferation of B cells 
and antibody production (Donaldson, 2007; Lilic, 2009). Phagocytosis, swelling, fever, and 
leukocyte proliferation, commonly referred to as inflammation, will continue until the pathogen 
is eliminated. 
 When experiencing stress, such as weaning, tumor necrosis factor alpha (TNF), released 
from macrophages and monocytes, stimulates CRH secretion from the hypothalamus, thus 




section will discuss how cortisol affects the immune system. The glucocorticoid receptor (GR) is 
found within the cytoplasm of immune cells. Cortisol must diffuse into the cell and bind its 
receptor in order to evoke a response (Adcock, 2000). Cortisol modulates cytokine production, 
decreases adhesion, trafficking, maturation, and migration of immune cells, and decrease 
inflammatory mediators such as prostaglandins. (Webster et al., 2002; Dolan-O’Keefe and Nick, 
1999). Generally, cortisol promotes anti-inflammatory responses and suppress pro-inflammatory 
responses. This is performed by control of cytokine transcription and disruption of signaling 
mechanisms (Bianchi et al., 2000). Cortisol performs a crucial task of controlling inflammation; 
therefore preventing self injury during the immune response. However, over stimulation of the 
HPA axis can result in suppression of the immune system, consequently increasing susceptibility 
to disease (Craddock, 1978). This is seen in times of intense environmental or physiological 
stress, such as weaning (McLamb et al., 2013; Bomba et al., 2014). Intense stress jeopardizes 
immune function and the effects of stress have been observed in human and animal studies. For 
example, an increase in swine intestinal disease is associated with weaning (McLamb et al.,2013; 
Bomba et al., 2014) and in humans, chronic stressors such as school exams or work stress 
increase the risk of acquiring viral infections and prolong wound healing (Rozlog, 1999) and 
marital distress causes long term immune cell dysfunction (Jaremka et al., 2013).  
 
Previous Efforts to Relieve the Post-Wean Lag 
 Because of its associated costs, many researchers have investigated methods of 
alleviating the post-weaning growth lag in pigs. A decrease in serum zinc concentrations at the 
time of weaning was observed. Because zinc plays a role in growth, experiments were conducted 




difference in weight gain was observed after treatment. Addition of glutamine to feed was 
successfully used to prevent jejunal atrophy in newly weaned pigs (Wu et al., 1996); however, 
increased growth was not observed until two weeks after weaning. Addition of spray-dried 
plasma to nursery diets has been used to increase feed intake after weaning (Touchette et al., 
2002; Kojima et al., 2007). Recently, the use of spray-dried plasma was questioned due to 
possible contamination and subsequent spread of Porcine Epidemic Diarrhea Virus (PED; Polo et 
al., 2014). Recent research has examined the use of syndyphalin-33 (SD-33; a synthetic opioid) 
to alleviate the negative effects of weaning (Jenkins et al., 2009; Kojima et al., 2009; Cooper et 
al., 2011). Syndyphalin-33 did alleviate the post-wean growth lag, but would be difficult to use 
in production because of its classification as a synthetic enkephalin. However, because of its 
success, more research is being conducted to examine alternate methods of increasing 
endogenous opioid tone (see Chapter 2). This literature review will now discuss opioids, their 
receptors, and their effects on immune modulation and feed intake.  
 
Opioids 
Opioids are peptides that can be found within animals and some plants or synthesized in a 
laboratory for medical use. Endogenous opioids are produced within the body and include 
endorphins, enkephalins, and dynorphins. They bind to three different types of opioid receptors 
found on cell membranes throughout the body: mu (, MOR), kappa (, KOR), and delta (, 
DOR) (Koneru et al., 2009; Ninkovic and Roy, 2013). When bound to their receptors, opioids 
can produce analgesic and euphoric effects in addition to affecting the immune system and 
appetite regulation (Koneru et al., 2009; Ninkovic and Roy, 2013). When bound, MORs are 




immunosuppression, and physical dependence (Koneru et al., 2009; Al-Hashimi et al., 2013). 
Activated KORs cause sedation, affect appetite, and inhibit the release of anti-diuretic hormone 
(ADH, Koneru et al., 2009; Yeomans and Gray, 2002). Bound DORs also produce analgesia, 
euphoria, and physical dependence. Endorphins bind with high affinity to mu and delta receptors. 
Enkephalins preferentially bind to delta receptors and dynophins bind to kappa receptors 
(Koneru et al., 2009). The following sections will cover how opioids modulate immunological 
functions and appetite regulation. 
 
Effects of Opioids on Immunological Functions 
 The effect of opioids on immune function is a topic of high controversy, and has been 
reviewed by Al-Hashimi and others (2013). Increased incidence of disease has been observed in 
opioid abusers and medical patients receiving chronic opioid medications (Hussey and Katz, 
1950; Risdahl et al., 1998).The effects of opioids on the adaptive immune system are numerous 
and include a decrease in T-cell viability and T-helper cell function (Bryant et al., 1988a, 1988b, 
1991; Roy et al., 2001), decrease in natural killer cell function (Gaveriauz-Ruff et al., 1998),  
decrease in macrophage activity (Bussiere et al., 1993), and an increase in the anti-inflammatory 
cytokines TGF-B1 and IL-10 (Pacifici et al., 2000). The innate immune system is also affected. 
Decreases in leukocyte migration (Casellas et al., 1991), chemotaxis (Simpkins et al., 1984; 
Perez-Castrillon et al., 1992; Grimm et al., 1998), and phagocytosis (Casellas et al., 1991; Szebo 
et al., 1993) have been observed with administration of opioids. According to Sacerdote (2006), 
drug and host factors, in addition to the duration of exposure, all influence how various opioids 
affect immune function. It is believed that the MOR is primarily responsible for the 




is supported by research using MOR knockout mice, where immune modulation is not observed 
(Gaveriaux-Ruff et al., 1998; Roy et al., 1998; Nelson et al., 2000).  
The locations of immunomodulation are controversial and may include the central neuro-
endocrine, central neuro-paracrine, and peripheral mechanisms (Al-Hashimi et al., 2013). The 
theory of central control is supported by the observation that opioids that are unable to cross the 
blood-brain barrier show less immune modulation than those that do (Shavit et al., 1986; 
Hernandez et al., 1993). The theory of peripheral control is supported by research using MOR 
knockout mice, which reports that no immune modulation occurs without the receptor present on 
immune cells (Gaveriaux-Ruff et al., 1998; Roy et al., 1998; Nelson et al., 2000). The HPA axis 
also plays a role in immune modulation. Endogenous and exogenous opioids have been shown to 
modulate the HPA axis ensuing in varied results that are dependent on an acute or chronic 
administration of the opioid (Vuong et al., 2010). Acute administration (results measured within 
24-hours of a single dose) results in an increase in ACTH and glucocorticoid levels in animals. 
Chronic administration (results measured after many days of administration) results in a 
decreased response of glucocorticoids to activation of the HPA axis (Vuong et al., 2010).  
 
Effects of Opioids on Appetite 
 Opioids are involved in the homeostatic and hedonic (pleasure) mechanisms of feed 
intake (Nogueiras et al., 2012). The MOR and KOR receptors are most active in feed intake 
regulation (Yeomans and Gray, 2002). When activated, opioid receptors located on pre- and 
postsynaptic POMC neurons inhibit firing, therefore increasing feed intake (Pennock and 
Hentges, 2011). Previous research shows that administration of naloxone, an opioid receptor 




Y (Rudski, et al., 1996; Hagan et al., 2001). Opioid administration can also affect the rewarding 




, Gly-ol]- enkephalin (DAMGO), a MOR agonist, was 
injected into the nucleus brain of rats, resulting in increased intake of saccharin and increased 
feeding in satiated rodents, respectively (Zhang and Kelley, 2002; MacDonald et al., 2003). 
Obese et al. (2006) reported that syndyphalin-33, a synthetic opioid, increased feed intake in 
sheep and demonstrated that the effects of syndyphalin-33 were temporarily canceled by 
administration of naloxone at 6 and 8 hours post-treatment. Cooper et al. (2011) observed an 
increase of MOR expression within the hypothalamus of control animals at the time of weaning, 
but not in pigs treated with 0.5µmole/ kg syndaphalin-33. Also, treatment with syndyphalin-33 
abrogated the increase of MC4R expression in control animals caused by weaning. Finally, 
Cooper et al. (2011) observed an increase in AGRP expression 4 days post-weaning in animals 
treated with syndyphalin-33. All of these changes in appetite regulating genes seen after 
syndyphalin-33 treatment support the theory that opioids are important regulators of appetite. 
 
Antagonist Induced Endogenous Opioid and Receptor Up-regulation 
 Weaning affects appetite regulation and immunological function. Specifically, cortisol 
released during times of stress decreases expression of appetite stimulating genes and decreases 
immune cell adhesion, trafficking, maturation, and migration. Because of their ability to increase 
appetite and decrease inflammation, opioids have been considered as a means to alleviate the 
post-weaning growth lag in pigs. However, opioid administration in commercial swine 
production is not feasible due to strict regulations and human abuse potential. Zagon and 
McLaughlin (1989) proposed a theory saying that a small, transient administration of an opioid 




opioids and their receptors. This hypothesis has been supported by others (Brown and Panksepp, 
2009; Younger et al., 2014). The increase of opioid concentrations and receptors would 
supersensitize opioid function within the body (Zukin et al., 1982; Brown and Panksepp, 2009); 
potentially resulting in effects similar to exogenous opioid administration. These effects may 
include increasing anti-inflammatory cytokines such as TFG-B1 and IL-10 and decreasing 
leukocyte migration and chemotaxis. Recent research has observed that low-doses of naltrexone 
can relieve the symptoms of human auto-immune diseases. Since inflammation is a common 
factor between auto-immune diseases in humans and weaning stress in pigs, a logical next step 
would be to examine the effects of low-dose naltrexone on pigs at weaning. 
 
Low Dose Naltrexone 
Naltrexone is a synthetic opioid-receptor antagonist. It binds with high affinity to MOR 
and DOR and with a lower affinity to KOR within the body (Weerts et al., 2008). It is orally 
effective and has a 4 hour half-life, reaching peak levels one hour after administration (Kleber, 
1985; Lobmaier et al., 2010). Its major metabolite, 6-beta-naetrexol, has a half-life of 13 hours, 
allowing the antagonistic effects of naltrexone to last for days (Kleber, 1985). When 
administered for treatment of narcotic addiction and alcoholism, normal dosages range from 50-
100 mg daily (Weinrieb and O’Brien, 1997; Lobmaier et al., 2010; Younger et al., 2014). An 
average low-dose naltrexone treatment in human medicine is 4.5 mg daily, though the dose can 
vary within a few milligrams (Younger et al., 2014). Low-dose naltrexone has been used to 
reduce symptoms of fibromyalgia (Younger and Mackey, 2009; Younger et al., 2013), Crohn’s 
disease (Smith et al., 2007), and multiple sclerosis (Cree et al., 2010). In the pilot study by 




of two weeks resulting in decreased levels of pain and stress. Furthermore, the effects of 
naltrexone were still being observed two weeks after cessation of treatment (Younger and 
Mackey, 2009). The symptoms of Crohn’s disease were reduced in patients receiving 4.5 mg 
naltrexone/ day, and 67% of the patients went into complete remission (Smith et al., 2007). 
Naltrexone given at 4.5mg/d improved mental health and pain in multiple sclerosis patients (Cree 
et al., 2010). Low-dose naltrexone administered at 0.1, 1.0, and 3.0 mg was found to decrease 
feed intake and to increase lying time in rats (Wright and Rodgers, 2013, 2014a, 2014b). To date, 
the Food and Drug Administration (FDA) has not done any testing to determine the withdrawal 
period of naltrexone in food animals. 
 
Conclusion 
 Weaning causes disruptions in immunity and appetite. The post-weaning growth lag has 
been a subject of research over the past few years, and low-dose naltrexone shows promise in 
alleviating the negative effects of weaning. It has been shown to reduce inflammation and stress 
in human studies and alter feed intake and behavior in rodent studies. The following chapter 











Effects of low-dose naltrexone on feed intake, growth, endocrine and immune parameters 
in the recently-weaned pig 
 
Introduction 
 Weaning stress causes decreased feed intake, poor growth, and increased susceptibility to 
disease in pigs (Matteri et al, 2000; Kojima et al., 2007, 2008; Jenkins et al., 2009). These 
responses to stress can manifest as a growth lag, but may also manifest as increased herd 
morbidity or mortality, particularly in conditions of poor herd health and management. Previous 
researchers have published findings that syndyphalin-33, a synthetic enkephalin, can negate the 
negative effects of weaning by increasing feed intake, plasma growth hormone levels, and 
circulating leukocyte numbers (Kojima et al., 2009). However, syndyphalin-33 is an opioid and 
would therefore be difficult to approve for production use.  
Naltrexone is a long acting (4 hour half-life), orally effective opioid antagonist that binds 
with high affinity to µ receptors throughout the body. It also binds  and  receptors but with 
lower affinity (Shader, 2003). Often, naltrexone is used for treatment of alcohol and narcotic 
addiction (Davidson et al., 1999); additionally, in low doses, naltrexone has been used to reduce 
symptoms of fibromyalgia (Younger and Mackey, 2009; Younger et al., 2013) and Crohn’s 
disease (Smith et al., 2007). In the pilot study by Younger and Mackey (2009), human 
participants were given 4.5 mg naltrexone/d for a period of two weeks resulting in decreased 
levels of pain and stress. Furthermore, Younger and Mackey (2009) published findings that the 
effects of naltrexone were still being observed two weeks after cessation of treatment. The most 
prevalent hypothesis is that a temporary blockade of opioid receptors on immune cells and 




their receptors, resulting in an overall increase in opioid tone (Zagon and McLaughlin, 1989, 
1995; Tempel et al., 1985; Brown and Panksepp, 2009).  
The hypothesis is that administering low doses of naltrexone orally to pigs two weeks 
prior to weaning would result in altered feed intake and weight gain due to the up-regulation of 
endogenous opioids and their receptors. This research examined the effects of low-dose 
naltrexone on growth, feed intake, and circulating measures of cortisol, corticosteroid-binding 
globulin, and immune cell populations in the recently weaned pig. 
 
Materials and Methods 
Forty-eight pigs (3.7 +/- 0.1 kg) were randomly assigned to four treatment groups of 12 
pigs per group at approximately 10 days of age. The four treatment groups included a control (0 
mg/d; N0) and three naltrexone treatments:  1 mg/d (N1), 5 mg/d (N5), and 10 mg/d (N10). 
Naltrexone was compounded with dextrose into size 4 capsules by the University of Tennessee 
College of Veterinary Medicine pharmacy and was administered orally once daily at the same 
time each morning for 14 days prior to weaning. Control animals received dextrose capsules to 
prevent differences in results due to handling. The pigs were manually restrained, dosed using a 
pill gun, and immediately returned to their dam and litter. At weaning, (d 0, approximately 28 
days of age) the pigs were weighed and blood samples collected via jugular venipuncture. Pigs 
were weaned into twelve 16 m
2
 pens by treatment (4 pens per treatment group, 3 pigs per pen). 
On d 1, 4, and 7 after weaning, the pigs were weighed and blood samples were collected. Feed 
and water were provided ad libitum. Cumulative post-weaning feed intake per pen was 




 Blood samples (approximately 4 mL) were collected via anterior venipuncture and 
allotted as follows: 1 mL into a tube spray-coated with 5.4 mg K₂-EDTA (BD Vacutainer, 
Franklin Lakes, NJ), and 3 mL into a tube spray-coated with 86 IU heparin (BD Vacutainer) for 
plasma collection. Blood collected into the EDTA- containing tubes was used to create white 
blood cell (WBC) differential slides and was also used in a hematology analyzer for 
measurement of white blood cell count (WBC). The heparinized blood samples were centrifuged 
at 801 g for 15 minutes and the recovered plasma was used for measurement of total cortisol 
concentrations and corticosterioid-binding globulin (CBG) concentrations (see below). The free 
cortisol index was calculated for each sample. 
During blood collection, animals were temporarily placed in a V-trough and restrained by 
hand. Collection of the sample was achieved within 1 minute of initial restraint to reduce 
restraint-related increases in cortisol concentration within the sample. 
Slides for WBC differentials were made from whole blood smears (approximately one 
cell layer thick), fixed in methanol, and stained with a Wright-Giemsa I and II Solution (Fisher 
Scientific, Houston, TX) according to the manufacturer’s directions. One hundred leukocytes 
were counted using light microscopy at 600x total magnification. The following leukocytes were 
counted: monocytes, lymphocytes, immature neutrophils (bands), neutrophils, eosinophils, and 
basophils. This paper will discuss the percentage of leukocytes identified as monocytes, 
neutrophils, and lymphocytes. The neutrophil/lymphocytes ratio (NLR) was calculated for each 
sample. 
A hematology analyzer (Vet ABC by Scil, Gurnee, IL) was used to quantify WBC. This 
machine was operated according to the manufacturer’s instructions using blood from EDTA-




Plasma total cortisol concentration was determined using the Coat-a-Count 
radioimmunoassay procedure (Diagnostic Products, Los Angeles, CA) as described previously 
(Scroggs et al, 2002). Intra- and interassay CV were 10.0% and 9.2% respectively for low and 
3.0% and 5.6% respectively for high cortisol quality control standards. The sensitivity of this 
assay ranged from 9.66 to 551.8 nmol/L. Plasma CBG concentration (mg/L) was measured by 
direct enzyme-linked immuno-absorbent assay (ELISA) as described previously (Roberts et al., 
2003). Intra- and interassay CV were 5.86% and 15.31%, respectively for CBG quality control 
standards. The sensitivity of this assay ranged from 0.05 mg/L to 400 mg/L. The free cortisol 
index (FCI, nmol/mg), was calculated using the ratio of concentrations of plasma total cortisol to 
CBG (Adcock et al., 2007). 
 
Statistical Analysis 
All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). A 
mixed model ANOVA with repeated measures was used to analyze body weight, cortisol, CBG, 
FCI, and all other blood values with pig as the experimental unit. All variables using repeated 
measures had time, treatment, and interaction as fixed effects. Pre-treatment weight was used as 
a covariate for body weight, and FCI required a log transformation to maintain homogeneity of 
variance. Cumulative feed intake was analyzed using a one-way ANOVA with pen as the 
experimental unit and treatment as the main effect. Total weight gain over 7 days post-weaning 
was analyzed using a one-way ANOVA with pig as the experimental unit and treatment as the 
main effect.  Least squares means were compared using Fisher’s protected LSD for all analyses, 









 Cumulative feed intake from d0- d7 differed between treatments (P= 0.0472), but was not 
different between N0 and N1 (Figure 1A). A decrease in feed intake was found in N5 (15.35  
0.54 kg) as compared to N0 (17.61  0.54 kg; P= 0.0121) and N1 (17.27  0.54 kg; P= 0.0278). 
Cumulative feed intake of N10 did not differ from other treatment groups. 
Body Weight: 
 Body weight differed by time (P < 0.0001) and a trend toward a time by treatment 
interaction was observed (P = 0.0581). Body weights did not differ between d 0 (8.04  0.15 kg) 
and d 1 (7.99  0.15 kg), but all four treatment groups gained weight from d 1 to d 4 (8.33  0.15 
kg) and from d 4 to d 7 (8.99  0.15 kg; Figure 1B). Body weight did not differ across treatment 
groups on d 0 or d 1. Body weight on d 4 differed between N5 and N10 where animals in N5 
(8.81  0.29 kg) weighed more than the animals in N10 (7.85  0.29 kg; P = 0.0239). On d 7, 
body weight differed between N0 and N5 such that animals in N5 (9.40  0.29 kg) weighed more 
compared with animals in N0 (8.36  0.29 kg; P=0.0148). 
Total Gain: 
 Total gain over 7 days post-weaning was greater in all naltrexone treatments (1.3  0.21; 
1.08  0.21; and 1.04  0.21 kg for N1, 5, and 10, respectively) as compared to the control group 
(0.33  0.21 kg; P= 0.0154; Figure 1C). There was no difference observed in total gain between 




Blood Characteristics:  
Plasma cortisol concentrations (PCC) are depicted in Figure 2A. An effect of time was 
observed (P < 0.0001) such that PCC increased from d 0 (89.40  6.62 nmol/L) to d 1 (145.57  
6.80 nmol/L), and then decreased to d 0 concentrations on d 4 (89.34  6.62 nmol/L). 
Concentrations remained unchanged from d 4 to d 7 (79.94  6.55 nmol/L). A time by treatment 
interaction was noted (P < 0.0001). On d 0, PCC did not differ between treatment groups. On d 
1, N10 (203.65  13.11 nmol/L) had greater PCC than all other treatments.  N0 had greater PCC 
on d 1 than N1 and N5 (153.81  13.11; 114.97  13.11; and 109.87  14.95 nmol/L for N0, 1, 
and 5 respectively). By d 4, PCC in N1, N5, and N10 (77.47  13.11; 84.72  13.11; 75.80  
13.64 nmol/L for N1, 5, and 10 respectively) decreased and were less than concentrations 
observed in N0 (119.36  13.11 nmol/L). No differences in PCC were observed among 
treatments on d 7.  
 Plasma CBG concentrations are depicted in Figure 2B. An effect of time was observed (P 
< 0.0001) such that CBG decreased from d 0 (1.64  0.09 mg/L) to d 1 (0.92  0.09 mg/L). 
Plasma concentrations of CBG did not differ between d 1 (0.92  0.09 mg/L) and d 4 (0.77  
0.09 mg/L) or between d 4 (0.77  0.09 mg/L) and d 7 (0.88  0.09 mg/L). 
 The FCI is depicted in Figure 2C. An effect of time was observed (P < 0.0001) such that 
the FCI increased from d 0 (58.71  6.10 nmol/mg) to d 1(168.96  20.40 nmol/mg). The FCI 
decreased from d 1 to d 4 (127.33  15.09 nmol/mg) and decreased from d 4 to d 7 (101.73  
11.99 nmol/mg). A time by treatment interaction was also observed (P = 0.0099). There was a 





Total WBC concentrations are depicted in Figure 3A. There was an effect of time (P < 
0.0001) such that WBC concentrations were not different between d 0 and d 1; however, d 7 













) in all treatments. 
 The percentage of leukocytes that were identified as monocytes (%mono) are depicted in 
Figure 3B. An effect of time was observed (P < 0.0001) such that from d 0 (9.93  0.86 %) to d 1 
(14.15  0.84 %), %mono increased, but was unchanged from d 1 to d 4 (13.98  0.84 %). An 
increase in %mono occurred from d 4 to d 7 (17.92  0.84 %). An interaction between time and 
treatment was also observed (P = 0.0073). On d 0 and d 1, %mono did not differ between 
treatment groups. On d 4, N0 and N1 differed in that N1 (10.75  1.67 %) animals had lower 
%mono than those in N0 (16.67  1.67 %; P = 0.0133). On d 7, animals in N10 differed from 
animals in N0 in that %mono was less in N10 (14.61  1.74 %) animals as compared to N0 (21.0 
 1.67 %; P = 0.0089). 
The percentage of leukocytes identified as neutrophils (%neut) differed by time (P < 
0.0001; Figure 4A). An increase from d 0 (24.16  1.61 %) to d 1 (45.38  1.57 %) was observed 
in %neut. The percentage of neutrophils decreased from d 1 to d 4 (39.38  1.57 %), and 
continued to decrease from d 4 to d 7 (35.48  1.57 %). An interaction between time and 
treatment was also observed (P = 0.0287). No differences between treatment groups were 
observed on d 0 or d 1. On d 4, %neut was less in N0 (34.83  3.14 %) as compared to N1 (46.17 
 3.14 %; P = 0.0118). N5 and N10 were not different than N0 or N1 on d 4 (38.08  3.14 % and 
38.42  3.14 % for N5 and 10 respectively). On d 7, no differences between treatment groups 




 The percentage of leukocytes that were identified as lymphocytes (%lymp) differed by 
time (P < 0.0001; Figure 4B). A decrease in %lymp occurred on d 1 (39.50  1.64 %) relative to 
d 0 (63.80  1.67 %) An increase in %lymp was observed on d 4 (45.06  1.64 %) relative to d 1 
but did not differ between d 4 to d 7 (45.0  1.64 %).  
 The neutrophil to lymphocyte ratio (NLR) did not differ by treatment but an effect of 
time was observed (P < 0.0001; Figure 4C) such that ratios increased from d 0 (0.39  0.09) to d 
1 (1.34  0.09) and decreased from d 1 to d 4 (1.01  0.09). The NLR was unchanged from d 4 to 
d 7 (0.86  0.09). An interaction between time and treatment was also noted (P = 0.0255). On d 
0, NLR did not differ between treatment groups. On d 1, NLR was less in N1 (1.06  0.17) 
relative to N0 (1.73  0.17; P = 0.0056). On d 4 and d 7, there were no differences in NLR 
observed between treatments. 
 
Discussion 
Recently researchers have observed the potential of low-dose naltrexone to alter pain, 
stress, and immune function (Smith et al., 2007; Younger and Mackey, 2009; Younger et al., 
2013). A theory has been put forth stating that low-dose naltrexone up-regulates endogenous 
opioids and opioid receptors (Zagon and McLaughlin, 1989). In the present study, a low-dose 
therapy of naltrexone prior to weaning was hypothesized to improve post-wean performance in 
pigs. The effects of low-dose naltrexone on growth, feed intake, and circulating measures of 
cortisol, corticosteroid-binding globulin, and immune cell populations were examined in the 
recently weaned pig. The various dosages were selected based on previous low-dose naltrexone 
research performed by Younger and Mackey (2009) in which naltrexone (4.5 mg) was 




participants had less pain, fatigue, and stress. Ramanathan and others concluded that it takes 
approximately two weeks to alter the endorphin system; therefore, we elected to administer the 
naltrexone treatment two weeks prior to weaning. 
 
Feed Intake (FI):  
Inhibition of piglet growth rate caused by weaning is well recognized and clearly 
associated with reduced FI (Bark et al., 1986; McCracken et al., 1995; Cooper et al., 2009). In 
this experiment, cumulative FI decreased in animals treated with 5 mg/d naltrexone during the 
two weeks prior to weaning as compared to the control. Opioid antagonist promote POMC 
expression and blocks AGRP binging to MC4R. Both of these effects inhibit appetite. Although 
we hypothesized that low-dose naltrexone would increase feed intake by promoting endogenous 
opioid concentrations, it seems that administration of even low-doses of an antagonist can still 
inhibit appetite. This study did not observe a difference in FI in animals treated with 1 mg/d or 
10 mg/d naltrexone as compared to control animals. In studies examining the effects of low-dose 
naltrexone on FI in rats (Wright and Rodgers, 2013, 2014a, 2014b), researchers administered 0.1 
mg/kg, 1.0 mg/kg, or 3.0 mg/kg of naltrexone by a single IP injection. Behavior and FI were 
examined for one hour starting fifteen minutes after drug administration. A decrease in FI was 
observed at all dosages. In a study by Avena and others (2014), rats were given an IP injection of 
0.1 mg/kg naltrexone. FI was measured hourly after injections at 1, 2, 3, 4 and 12 hr. FI 
decreased at 12 hr post injection of 0.1mg/kg naltrexone, and increased at 1 hr post injection of 
0.1mg/kg naltrexone. It should be noted that these studies examined the effects of naltrexone 
immediately after 1 dose, whereas, this study administered naltrexone daily through two weeks 




naltrexone affects feed intake is complicated. It has been shown that endogenous opioids are an 
important part of appetite regulation and that administration of an opioid antagonist, such as 
naltrexone, decreases appetite (Nogueiras et al., 2012).  
Body Weight (BW):  
After an initial lag in growth from d 0 to d 1 caused by weaning, all treatment groups 
recovered so that weights were greater on d 4 and still increasing on d 7. This pattern of growth 
after weaning has been observed by many researchers (Bark et al., 1986; McCracken et al., 1995; 
Cooper et al., 2009; Cooper et al., 2011). Four days after weaning, animals treated with 5 mg/d 
naltrexone pre-weaning weighed more than those treated with 10 mg/d naltrexone before 
weaning, and 7 days post-weaning animals treated with 5 mg/d naltrexone before weaning 
weighed more than the control animals. To date, no previous research has been published 
evaluating the long term effect of low-dose naltrexone on weight gain in any species.  
Interestingly, animals treated with 5 mg/d naltrexone also had decreased FI. An increase 
in feed efficiency is possible; the animals could be partitioning energy toward growth rather than 
behaviors such as fighting. Wright and Rodgers (2013) observed an increase in resting behavior 
in rats fifteen minutes after being treated with 3.0 mg/kg naltrexone as compared to the control 
group. It would be beneficial to observe post-weaning piglet behavior in future studies to 
establish if low-dose naltrexone decreases energy-wasting fighting behavior.  Animals treated 
with 10 mg/d naltrexone experienced effects similar to animals treated with high doses of 
naltrexone.  Typical daily dosages of naltrexone used for opioid addiction range from 50 mg/d to 
100 mg/d (Younger et al., 2014) and have been shown to decrease appetite and weight gain 
(Billes et al., 2014). The dosage of 10mg/d used in this study is lower than average naltrexone 





All the animals in this study receiving naltrexone treatments gained more weight over 
seven days post-weaning than animals in the control group. As mentioned above, no previous 
research has examined the long term effects of low-dose naltrexone on weight gain. The animals 
administered 10 mg/d naltrexone did not differ in BW from the control at any point in the study; 
however they ended the study weighing slightly more on average than the control animals. This 
difference caused a significant increase in gain in the animals treated with 10mg/d naltrexone. 
Also, those animals experienced an extended growth lag until d 4, suggesting that 10mg/d is not 
ideal for the purposes of increasing post-wean performance in pigs.  
Plasma Cortisol: 
Plasma cortisol concentrations (PCC) increased 24 hr after weaning as expected and 
previously reported by many researchers (Le Dividich and Seve, 2000; Kojima et al., 2008; 
Cooper et al., 2009). The effects of weaning on PCC were abrogated by treatment with 1mg/d 
naltrexone and 5mg/d naltrexone 1 d after weaning. Furthermore, PCC in animals treated with 10 
mg/d naltrexone were higher than PCC in control animals 1d after weaning. This result is 
consistent with the concept that 10 mg/d naltrexone is too high a dose, resulting in increased 
cortisol levels similar to research using high doses (50-100mg daily) of naltrexone (Kosten et al., 
1986; Ray et al., 2009). Previous research has shown that opioid drugs have the ability to affect 
adrenal gland function, therefore decreasing PCC (Pirnik et al, 2001; Daniell, 2006). However, 
no reports have been published describing the effects of low-dose naltrexone on PCC.  
Corticosterioid-Binding Globulin (CBG): 
Plasma corticosterioid-binding globulin concentrations decreased 1 d after weaning in all 




concentrations at weaning (Kojima et al., 2008; Cooper et al., 2009). Concentrations remained 
lower than pre-weaning levels seven days post-weaning. Nock and colleagues (1997) found that 
administration of the opioid morphine could up-regulate CBG levels in rats. The morphine 
treatment was administered by a subcutaneous pellet up to 14 days. In the present study, 
administration of low-dose naltrexone did not elicit similar effects; no previous research has 
examined the effects of low-dose naltrexone on CBG concentrations.  
Free Cortisol Index (FCI): 
The free cortisol index increased 1 d post-weaning in all treatment groups. After this 
initial increase, the FCI steadily decreased from d 1 to d 7 of this study. This increase of FCI at 
weaning has been observed previously (Kojima et al., 2008; Cooper et al., 2009). Only animals 
receiving 1 mg/d naltrexone returned to pre-weaning levels of FCI by d 7. It is important to 
mention that the FCI is a ratio of plasma cortisol concentrations and corticosteroid-binding 
globulin concentrations. Because of this, the FCI is not very sensitive to changes in PCC. To 
date, no research has been published showing the effects of opioids or low-dose naltrexone on 
the FCI.  
White Blood Cells: 
Weaning stress causes increases in total WBC count, percentage of neutrophils and 
monocytes, and an increase in the neutrophil to lymphocyte ratio (Kojima et al., 2008, 2009; 
Jenkins et al., 2009; Cooper et al., 2009; Bomba et al., 2014). In the present study, no differences 
were seen across treatment groups over 7 d post-weaning in any counted WBC population. Total 
WBC count did not change from d 0 to d 1, but increased from d 1 to d 7. The percentage of 
neutrophils and monocytes increased from d 0 to d 1, similar to results published by Cooper and 




initially decreased on d 1, but increased from d 1 to d 4, a trend also seen by Cooper and others 
(2009).  
Opioids, such as morphine, are considered immunosuppressive, and have also been 
shown to decrease inflammation by decreasing leukocyte migration and chemotaxis, leukocyte 
proliferation, and inflammatory cytokine release including IL-1 and IL-6 (Ninkovic and Roy, 
2013). Low-dose naltrexone has been used in research for treatment of auto-immune diseases 
such as fibromyalgia and Crohn’s disease. It has been theorized to increase B-endorphin, mu 
opioid receptor (, MOR), kappa opioid receptor (, KOR), and delta opioid receptor (, DOR) 
by temporarily blocking opioid receptors, resulting in down regulation of TNFa, IL-1 and IL-6 
(Ninkovic and Roy, 2013). This causes a shift from T-helper 1 cells (TH1) to T-helper 2 cells 
(TH2). Since T-helper 2 cells produce anti-inflammatory cytokines such as IL-4 and IL-10, low-
dose naltrexone has been termed anti-inflammatory (Brown and Panksepp, 2009; Younger et al., 
2014). 
Neutrophil to Lymphocyte Ratio (NLR): 
Stress can cause a systemic inflammatory response (Sutherland et al., 2006). During 
inflammation, numbers of circulating neutrophils increase causing the NLR to increase. The 
NLR has been considered an indicator of stress in many species including cattle, rhesus 
macaques, and swine (Sutherland et al., 2013; Lee et al., 2013; Khafipour et al., 2014; O’Driscoll 
et al., 2015). In the present study, no differences between treatment groups were present, and the 
NLR increased from d 0 to d 1 in all groups. This increase in the NLR was also observed by 
Cooper et al (2009). In the present study, the NLR on d 1 was less in animals given 1 mg/d 
naltrexone than in the control animals. A decrease in the NLR was observed in all treatment 




observed this decrease in the NLR 7 days post weaning. The effects of low-dose naltrexone and 




This study has demonstrated that pre-weaning treatment with low-dose naltrexone can 
result in increased weight gain and modulation of the commonly-observed immune and stress 
responses to weaning. The possibility that a low-dose pre-weaning naltrexone regimen could 
cause increased post-weaning feed efficiency through modulating behaviors should be examined 
further. The use of low-dose naltrexone in commercial swine production may represent a means 
to manifest the positive changes associated with opioid treatments without the negative aspects 
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Figure 1.  Cumulative feed intake (A), body weights (B) and cumulative gain (C) over the first 7 
days post-weaning.  Raw means and standard errors are shown.  Means with identical letters do 
not differ.  For (B), letters indicate sameness or difference of means relating to day post-
weaning; an asterisk indicates a time where there occurred a difference between the mean for 
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Figure 2.   Plasma concentrations of cortisol (A) and corticosteroid-binding globulin (B).  
Calculated free cortisol index (C). Raw means and standard errors are shown.  Means with 
identical letters do not differ; an asterisk indicates a time where there occurred a difference 







Figure 3.  Whole blood white blood cell (WBC) concentration (A) and percentage of WBC that 
were identified as monocytes (B).  Raw means and standard errors are shown.  Means with 
identical letters do not differ; an asterisk indicates a time where there occurred a difference 










Figure 4.  Percentage of WBC that were identified as neutrophils (A) and lymphocytes (B), and 
the calculated neutrophil:lymphocyte ratio (C).  Raw means and standard errors are shown.  
Means with identical letters do not differ; an asterisk indicates a time where there occurred a 
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